Skip to main content

Willow Biosciences Inc. to Webcast Live at Life Sciences Investor Forum September 17th   

Written by Customer Service on . Posted in Public Companies.

VANCOUVER, British Columbia, Sept. 14, 2020 (GLOBE NEWSWIRE) — Willow Biosciences Inc. (TSX: WLLW, OTCQX: CANSF), based in Vancouver, Canada, focused on manufacturing pharmaceutical grade quality cannabinoids via synthetic biology, today announced that Trevor Peters, President and Chief Executive Officer, will present live at LifeSciencesInvestorForum.com on September 17th.  
DATE: Thursday, September 17th
TIME: 2:30 PM ET
LINK: https://bit.ly/30GjErkThis will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.Learn more about the event at www.lifesciencesinvestorforum.com.Recent Company HighlightsIn July of 2020, Willow announced it had commenced its 500-liter pilot for its first cannabinoid. The pilot was ahead of schedule based on success of science and interest from multi-national consumer packaged goods companies.Samples from Willow’s pilot program will be available in September 2020 and will make Willow the first to biosynthetically produce material amounts of cannabinoids.In June 2020, Willow announced that it will be adding four more cannabinoids to its portfolio, in addition to CBD – CBG, CBGV, CBDV, THCV.Willow expects to commercialize its first cannabinoid in the first half of 2021.About Willow Biosciences Inc.Willow is a Canadian biotechnology company based in Vancouver, Canada, that produces high purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow’s current focus is in the production of cannabinoids for the treatment for pain, anxiety, obesity, brain disorders, among other significant indications. Willow’s science team has a proven track record of developing manufacturing technologies for high purity compounds in pain and cancer treatments. Willow’s manufacturing process creates a consistent, scalable and sustainable product that allows for the discovery and development of new life changing drugs.About Life Sciences Investor Forum
Life Sciences Investor Forum is the leading proprietary investor conference series that provides an interactive forum for Life Sciences companies to meet with and present directly to investors.A real-time solution for investor engagement, Life Sciences Investor Forum is powered by Intrado Digital Media and specifically designed for more efficient investor access. Replicating the look and feel of on-site investor conferences, Life Sciences Investor Forum combines leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.CONTACTS:
Willow Biosciences Inc.
Troy Talkkari, CFA
Vice President, Corporate Development
(403) 618-1117

Life Sciences Investor Forum
John M. Viglotti
SVP Corporate Services, Investor Access
(212) 220-2221

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.